MedTrace Logo

Role of Myo-inositol and D-chiro-inositol on Oocyte Quality

NCT01338844 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2011-06-01

No results posted yet for this study

Summary

Controlled ovarian hyperstimulation with gonadotropins is an integral part of the various stimulation protocols for patients undergoing in-vitro fertilization (IVF) and other Assisted Reproductive Technologies (ART) such as intracytoplasmic sperm injection (ICSI).

The hormonal control of multiple follicular growth and maturation is a critical part of ART procedures since it maximizes the yield of embryos to be transferred, thus increasing the cumulative pregnancy rate.

Recent studies have shown the efficacy of myo-inositol (MI) supplementation as a simple and highly effective treatment in order to improve oocyte quality in patients undergoing IVF. Indeed, it was previously shown that MI follicular fluid (FF) concentration is a reliable predictor of oocyte quality. High MI concentration in the FF directly correlates with high oocyte and embryo quality.

Another stereoisomer of Inositol was successfully used into clinical practice D-chiro-inositol (DCI). In particular, DCI supplementation was used to restore ovulation in hyperglycemic PCOS patients.

In the present study we aim to compare MI versus DCI supplementation on oocyte quality of women undergoing IVF-ET

Conditions

Interventions

DIETARY_SUPPLEMENT

Myo-inositol

DIETARY_SUPPLEMENT

D-chito-Inositol

Sponsors & Collaborators

  • Research Center for Reproductive Medicine Villa Mafalda

    collaborator UNKNOWN

  • San Raffaele University Hospital, Italy

    collaborator OTHER

  • AGUNCO Obstetrics and Gynecology Centre

    lead OTHER

Principal Investigators

  • Gianfranco Carlomagno, Ph.D. · AGUNCO Obstetrics and Gynecology Centre

  • Vittorio Unfer, M.D. · AGUNCO Obstetrics and Gynecology Centre

  • Franco Lisi, M.D. · Research Center for Reproductive Medicine

  • Enrico Papaleo, M.D. · San Raffaele Hospital

  • Scott Roseff, MD · The Palm Beach Center for Reproductive Medicine

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01338844 on ClinicalTrials.gov